327 related articles for article (PubMed ID: 10480527)
1. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes.
Scheen AJ; Lefèbvre PJ
Diabetes Care; 1999 Sep; 22(9):1568-77. PubMed ID: 10480527
[TBL] [Abstract][Full Text] [Related]
2. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control.
Gavin LA; Barth J; Arnold D; Shaw R
Endocr Pract; 2000; 6(4):305-10. PubMed ID: 11242607
[TBL] [Abstract][Full Text] [Related]
3. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial.
Yale JF; Valiquett TR; Ghazzi MN; Owens-Grillo JK; Whitcomb RW; Foyt HL
Ann Intern Med; 2001 May; 134(9 Pt 1):737-45. PubMed ID: 11329231
[TBL] [Abstract][Full Text] [Related]
4. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
5. Troglitazone in type II diabetes mellitus.
Sparano N; Seaton TL
Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
[TBL] [Abstract][Full Text] [Related]
6. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice.
Hershon KS; Hershon PM
Endocr Pract; 2000; 6(1):20-5. PubMed ID: 11419922
[TBL] [Abstract][Full Text] [Related]
7. [Combination therapy of insulin sensitizer, thiazolidinedione drugs, and sulfonylurea].
Ohmura E; Hosaka D; Imai Y; Kawazu S
Nihon Rinsho; 2002 Sep; 60 Suppl 9():470-5. PubMed ID: 12387036
[No Abstract] [Full Text] [Related]
8. Troglitazone: a new antihyperglycemic agent.
Vidt DG; Speerhas RA; Reddy SS
Cleve Clin J Med; 1997 May; 64(5):238-40. PubMed ID: 9149473
[TBL] [Abstract][Full Text] [Related]
9. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
10. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
11. Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.
Johnson MD; Campbell LK; Campbell RK
Ann Pharmacother; 1998 Mar; 32(3):337-48. PubMed ID: 9533065
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.
Chu NV; Kong AP; Kim DD; Armstrong D; Baxi S; Deutsch R; Caulfield M; Mudaliar SR; Reitz R; Henry RR; Reaven PD
Diabetes Care; 2002 Mar; 25(3):542-9. PubMed ID: 11874944
[TBL] [Abstract][Full Text] [Related]
13. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.
Yu JG; Kruszynska YT; Mulford MI; Olefsky JM
Diabetes; 1999 Dec; 48(12):2414-21. PubMed ID: 10580431
[TBL] [Abstract][Full Text] [Related]
14. The use of insulin alone and in combination with oral agents in type 2 diabetes.
Buse JB
Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
[TBL] [Abstract][Full Text] [Related]
15. [Troglitazone].
Yamanouchi T
Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
[TBL] [Abstract][Full Text] [Related]
16. Oral antihyperglycemic therapy for type 2 diabetes: scientific review.
Inzucchi SE
JAMA; 2002 Jan; 287(3):360-72. PubMed ID: 11790216
[TBL] [Abstract][Full Text] [Related]
17. Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled study. The Troglitazone Study Group.
Fonseca VA; Valiquett TR; Huang SM; Ghazzi MN; Whitcomb RW
J Clin Endocrinol Metab; 1998 Sep; 83(9):3169-76. PubMed ID: 9745421
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
19. The use of insulin secretagogues in the treatment of type 2 diabetes.
Luna B; Hughes AT; Feinglos MN
Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
[TBL] [Abstract][Full Text] [Related]
20. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
